Loading viewer...
investor_presentation
Format: PDF investor_presentation
Corporate Presentation Halozyme Therapeutics, Inc. June 5, 2020
Corporate Presentation
Halozyme Therapeutics, Inc.
June 5, 2020 Forward -Looking Statements
Inaddition tohistorical information, the statements setforth inthis presentation include forward -looking
statements including, without limitation, statements concerning the Company’s expected future financial
performance (including theCompany's financial outlook for2020 )and expectations forprofitability, revenue,
free cash flow, expenses and earnings -per-share and theCompany’s plans tocontinue itsshare repurchase
program and topotentially expand itsplatform through acquisitions .Forward -looking statements regarding the
Company’s ENHANZE®drug delivery technology may include thepossible activity, benefits and attributes of
ENHANZE®,thepossible method ofaction ofENHANZE®,itspotential application toaidinthedispersion and
absorption ofother injected therapeutic drugs and facilitating more rapid delivery ofinjectable medications
through subcutaneous delivery .Forward -looking statements regarding theCompany's ENHANZE®business may
include potential growth driven byourpartners' development and commercialization efforts (including expected
approval and product launch ofENHANZE®products), projections forfuture sales revenue ofourcollaborators’
products, potential new ENHANZE®collaborations, collaborative targets and co-formulation intellectual property,
and regulatory review and potential approvals ofnew ENHANZE®products .These forward -looking statements are
typically, butnotalways, identified through useofthewords "believe," "enable," "may," "will," "could," "intends,"
"estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of
similar meaning and involve riskand uncertainties that could cause actual results todiffer materially from those in
theforward -looking statements .Actual results could differ materially from theexpectations contained inthese
forward -looking statements asaresult ofseveral factors, including unexpected levels ofrevenues (including
royalty and milestone revenue received from ourcollaboration partners), expenditures and costs, unexpected
delays intheexecution oftheCompany's share repurchase program orplatform expansion, unexpected results
ordelays inthegrowth oftheCompany’s ENHANZE®business, obtaining new co-formulation intellectual property,
orinthedevelopment, regulatory review orcommercialization ofENHANZE®products, including any potential
delays caused bythe current COVID -19global pandemic, regulatory approval requirements, unexpected
adverse events orpatient outcomes and competitive conditions .These and other factors that may result in
differences arediscussed ingreater detail intheCompany's most recently filed Annual Report onForm 10-Kand
Quarterly Report onForm 10-Qfiled with theSecurities and Exchange Commission .
1Commercially Validated ENHANZE®Platform Poised to Drive
Preview truncated — download the full document for the complete content.
conference
20 Pages
investor_presentation
23 Pages
Live Oak Bancshares
investor_presentation
Ternium